MedTrace Logo

Amyloid Beta and Cognition in Parkinson Disease

NCT01754168 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2018-03-08

No results posted yet for this study

Summary

The investigators propose to study persons with Parkinson Disease (PD) with detailed clinical, cognitive and imaging at the time of study entry and repeat these assessments 2 years later. The study looks at how changes in activity of the neurotransmitter acetylcholine relates to changes in cognitive function and to see if there is presence or build up of amyloid protein.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Nicolaas Bohnen, M.D., Phd · University of Michigan

  • Roger Albin, M.D. · University of Michigan

  • Martijn Muller, PhD · University of Michigan

Eligibility

Min Age
65 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01754168 on ClinicalTrials.gov